Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL9779769 | 0.83 | SLC1A1 (0.58) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL8836944 | 0.82 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL27931897 | 0.82 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| Threonine SCHEMBL7587312 | 0.82 | SLC1A1 (0.57) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| Threonine SCHEMBL7587327 | 0.82 | SLC1A1 (0.57) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL8426348 | 0.82 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL6783795 | 0.81 | SLC1A1 (0.57) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| Valine SCHEMBL5616100 | 0.80 | SLC1A1 (0.50) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL800946 | 0.80 | SLC1A1 (0.55) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 | |
| SCHEMBL7494382 | 0.80 | SLC1A1 (0.55) | SLC1A1SLC1A3SLC1A2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-6017385-A | Ink compositions | XEROX CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
| US-5931995-A | Ink compositions | XEROX CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | SLC1A1 1973/4885SLC1A3 2260/4885SLC1A2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.